Historically, since neo-antigens have been produced by mutations, the greater the number of mutations (the higher the TMB), the higher the chance that some neo-antigens presented by Major histocompatibility complex (MHC) proteins will be immunogenic, enabling T cell recognition and cancer cell eradication [24–26]. This evidence concerns the gene HLA-C and cancer.